Results
1 -
10 of
16The Role of HGF/c-MET in Head and Neck Squamous Cell Carcinoma, Molecular Determinants of Head and Neck Cancer Rational Therapy for Renal Cell Carcinoma Based on its Genetic Targets, Impact of Genetic Targets on Cancer Therapy Forthcoming Drugs for Metastatic Renal Cell Carcinoma Therapy, Renal Cell Carcinoma Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas, Targeted Oncology A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers, Investigational New Drugs c-MET Inhibitors in the Treatment of Lung Cancer, Current Treatment Options in Oncology Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors, Clinical Pharmacokinetics Design, synthesis and pharmacological evaluation of novel 4-phenoxyquinoline derivatives as potential antitumor agents, Chemical Research in Chinese Universities Foretinib (XL880): c-MET Inhibitor with Activity in Papillary Renal Cell Cancer, Current Oncology Reports